Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/3083
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRajam, Gowrisankaren
dc.contributor.authorTzanakaki, Georginaen
dc.contributor.authorVadivelu-Pechai, Kumaranen
dc.contributor.authorWatson, Philipen
dc.contributor.authorVazquez, Julio A.en
dc.contributor.authorRappuoli, Rinoen
dc.contributor.authorMedini, Duccioen
dc.contributor.authorBorrow, Rayen
dc.contributor.authorMuzzi, Alessandroen
dc.contributor.authorBrozzi, Alessandroen
dc.contributor.authorSerino, Lauraen
dc.contributor.authorBodini, Margheritaen
dc.contributor.authorAbad, Raquelen
dc.contributor.authorCaugant, Dominiqueen
dc.contributor.authorComanducci, Maurizioen
dc.contributor.authorLemos, Ana Paulaen
dc.contributor.authorGorla, Maria Ceciliaen
dc.contributor.authorKřížová, Pavlaen
dc.contributor.authorMikula, Claudiaen
dc.contributor.authorMulhall, Roberten
dc.contributor.authorNissen, Michaelen
dc.contributor.authorNohynek, Hannaen
dc.contributor.authorSimões, Maria Joãoen
dc.contributor.authorSkoczyńska, Annaen
dc.contributor.authorStefanelli, Paolaen
dc.contributor.authorTaha, Muhamed-Kheiren
dc.contributor.authorToropainen, Maijaen
dc.date.accessioned2022-11-07T23:38:25Z-
dc.date.available2022-11-07T23:38:25Z-
dc.date.issued2019en
dc.identifier.citation37, (7), 2019, p. 991-1000en
dc.identifier.otherRISen
dc.identifier.urihttp://dora.health.qld.gov.au/qldresearchjspui/handle/1/3083-
dc.description.abstractBackground: The Meningococcal Antigen Typing System (MATS) was developed to identify meningococcus group B strains with a high likelihood of being covered by the 4CMenB vaccine, but is limited by the requirement for viable isolates from culture-confirmed cases. We examined if antigen genotyping could complement MATS in predicting strain coverage by the 4CMenB vaccine.; Methods: From a panel of 3912 MATS-typed invasive meningococcal disease isolates collected in England and Wales in 2007-2008, 2014-2015 and 2015-2016, and in 16 other countries in 2000-2015, 3481 isolates were also characterized by antigen genotyping. Individual associations between antigen genotypes and MATS coverage for each 4CMenB component were used to define a genetic MATS (gMATS). gMATS estimates were compared with England and Wales human complement serum bactericidal assay (hSBA) data and vaccine effectiveness (VE) data from England.; Results: Overall, 81% of the strain panel had genetically predictable MATS coverage, with 92% accuracy and highly concordant results across national panels (Lin's accuracy coefficient, 0.98; root-mean-square deviation, 6%). England and Wales strain coverage estimates were 72-73% by genotyping (66-73% by MATS), underestimating hSBA values after four vaccine doses (88%) and VE after two doses (83%). The gMATS predicted strain coverage in other countries was 58-88%.; Conclusions: gMATS can replace MATS in predicting 4CMenB strain coverage in four out of five cases, without requiring a cultivable isolate, and is open to further improvement. Both methods underestimated VE in England. Strain coverage predictions in other countries matched or exceeded England and Wales estimates. (Copyright © 2019 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.. All rights reserved.)Date of Electronic Publication: 2019 Jan 17. Current Imprints: Publication: Amsterdam, The Netherlands : Elsevier Science; Original Imprints: Publication: [Guildford, Surrey, UK] : Butterworths, [c1983- <br />en
dc.language.isoenen
dc.relation.ispartofVaccineen
dc.titleGenetic Meningococcal Antigen Typing System (gMATS): A genotyping tool that predicts 4CMenB strain coverage worldwideen
dc.typeArticleen
dc.identifier.doi10.1016/j.vaccine.2018.12.061en
dc.subject.keywordsGlobal Healthen
dc.subject.keywordsHumansen
dc.subject.keywordsMeningitis, Meningococcal/epidemiologyen
dc.subject.keywordsMolecular Epidemiology/methodsen
dc.subject.keywordsNeisseria meningitidis, Serogroup B/geneticsen
dc.subject.keywordsNeisseria meningitidis, Serogroup B/isolation & purificationen
dc.subject.keywords4CMenB vaccine*en
dc.subject.keywordsGenotyping*en
dc.subject.keywordsNeisseria meningitidis serogroup B*en
dc.subject.keywordsStrain coverage*en
dc.subject.keywordsgMATS*en
dc.subject.keywordsMeningococcal Vaccines/*immunologyen
dc.subject.keywordsMeningitis, Meningococcal/*microbiologyen
dc.subject.keywordsGenotyping Techniques/*methodsen
dc.subject.keywordsGenotype*Antigens, Bacterial/*geneticsen
dc.subject.keywordsNeisseria meningitidis, Serogroup B/*classificationen
dc.relation.urlhttps://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,athens&db=mdc&AN=30661831&site=ehost-liveen
dc.identifier.risid3668en
dc.description.pages991-1000en
item.grantfulltextnone-
item.openairetypeArticle-
item.fulltextNo Fulltext-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
Appears in Sites:Children's Health Queensland Publications
Show simple item record

Page view(s)

60
checked on Apr 22, 2025

Google ScholarTM

Check

Altmetric


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.